Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
521-540 of 1,694 trials

Rectal Adenocarcinoma: Contact X-Ray Brachytherapy Study

We are studying whether adding contact X-ray brachytherapy to standard treatment can help preserve the rectum and improve survival in patients with intermediate substage rectal adenocarcinoma. We will also assess its impact on quality of life and side effects.

Rectal Adenocarcinoma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyOncology

Alectinib Dosing: Standard vs. Personalized Approach

We are comparing standard alectinib dosing to a personalized dosing method based on blood levels for patients with specific alectinib concentrations. The goal is to see if personalized dosing improves treatment outcomes and safety.

ALK Positive Non-Small Cell Lung Cancer1-2 yearsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesOncologyPulmonology

Liver Cancer: Fecal Microbiota Transfer Study

We are investigating whether fecal microbiota transfer can help liver cancer patients who are resistant to standard treatments. The study aims to improve immune response and overall survival.

Non-resectable Hepatocellular Carcinoma>2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesHepatologyInternal MedicineOncology

Lung Cancer: Durvalumab and Domvanalimab Study

We are studying a combination of two medications for patients with stage III unresectable non-small cell lung cancer who have not progressed after initial treatment. The goal is to see if this combination improves survival and disease control compared to standard treatment.

Lung Cancer6-12 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Follicular Lymphoma: Epcoritamab with Rituximab and Lenalidomide

We are studying a new treatment combination for adults with previously untreated follicular lymphoma. The goal is to see if it works better and has fewer side effects than standard chemotherapy.

Follicular LymphomaConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Bone Health: Identifying Risks from Glucocorticoids

We are studying how to find biomarkers that indicate a risk of bone disease in people taking glucocorticoids. This research may help improve monitoring and prevention strategies for affected individuals.

Secondary Osteoporosis≤3 monthsEfficacy phase (II)≤5 visitsStandard MedicinesCost ReimbursementEndocrinologyRheumatology

Prostate Cancer: Pembrolizumab Combination Therapy

We are studying a new combination therapy with pembrolizumab for men with metastatic castration-resistant prostate cancer. The trial aims to evaluate its safety and how well it reduces PSA levels compared to standard treatments.

Metastatic Castration-Resistant Prostate CancerSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Alcohol Dependence: Sodium Oxybate Study

We are investigating whether Sodium Oxybate can help reduce alcohol consumption in people with high drinking risk levels. This study aims to support individuals in maintaining abstinence from alcohol.

Alcohol Addiction3-6 monthsConfirmation phase (III)6-10 visitsStandard MedicinesPsychiatry

Bomedemstat for Blood Disorders: Safety and Efficacy Study

We are studying the safety of bomedemstat for individuals with essential thrombocythemia, polycythemia vera, or myelofibrosis who participated in a previous study. The trial also examines how well the treatment manages these conditions over time.

Myeloproliferative Neoplasms>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyOncology

Glioblastoma Treatment: Lomustine and Temozolomide Study

We are studying whether a combination of lomustine and temozolomide improves survival for newly diagnosed glioblastoma patients with a specific genetic marker. This trial also looks at side effects and quality of life compared to standard treatment.

Glioblastoma6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesNeurologyOncology

Gene Therapy for Crigler-Najjar Syndrome: GNT0003

We are studying a new gene therapy to see if it is safe and effective for patients with severe Crigler-Najjar syndrome who need phototherapy. This trial will help us understand how it may improve their health and quality of life.

Crigler-Najjar Syndrome>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesPartially RemoteHepatology

Coronary Artery Disease: Angiolite Stent and Antiplatelet Therapy Study

We are evaluating whether a new stent and a shorter antiplatelet therapy can reduce complications in patients with coronary artery disease. This study compares these approaches to standard treatment options.

Coronary Artery Disease>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteCardiology

Ovarian Stimulation in Older Women: INOVEE Study

We are comparing two doses of a fertility medication to see which produces more healthy embryos in older women undergoing fertility treatment. This study aims to improve outcomes for women trying to conceive.

Female Infertility3-6 monthsMonitoring phase (IV)No PlaceboStandard MedicinesEndocrinologyGynecology and Obstetrics

Dilated Cardiomyopathy: Candesartan vs Placebo

We are studying whether early treatment with candesartan can help prevent heart function decline in people with a genetic risk for dilated cardiomyopathy who currently have no symptoms. The trial also looks at the safety of this medication.

Dilated Cardiomyopathy>2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesPartially RemoteCardiologyInternal Medicine

Plaque Psoriasis: JNJ-77242113 Treatment Study

We are studying a new medication for people with moderate to severe plaque psoriasis. The goal is to see if it works better than a placebo in reducing symptoms.

Plaque Psoriasis>2 yearsConfirmation phase (III)Investigational MedicinesPartially RemoteDermatology

Generalized Myasthenia Gravis: Iptacopan Study

We are studying a new treatment called iptacopan for people with generalized Myasthenia Gravis to see if it helps improve daily activities and muscle strength. The trial will also assess the safety of this treatment compared to a placebo.

AChR Myasthenia Gravis6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementInternal MedicineNeurology

Vitamin D Supplementation in Obese Children and Adolescents

We are comparing monthly versus daily vitamin D supplements to see which is more effective in raising vitamin D levels in obese children and teens. The study also looks at safety and how well participants follow the treatment.

Obesity in Children and Adolescents>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesEndocrinologyPediatrics

Breast Cancer: Vepdegestrant and Samuraciclib Study

We are investigating the safety and effectiveness of a new oral medication combined with another treatment for adults with advanced or metastatic hormone receptor-positive breast cancer. This study aims to find better treatment options for patients facing this condition.

Advanced Breast CancerSafety phase (I)Efficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Scleroderma-Related Lung Disease: Investigational Treatments

We are studying new treatments for interstitial lung disease in people with scleroderma to see if they improve lung function and overall health compared to a placebo.

Interstitial Lung Disease due to Systemic Sclerosis1-2 yearsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemotePulmonologyRheumatology

Labor Induction: Outpatient vs. Inpatient Methods

We are studying whether inducing labor at home is as safe and effective as doing it in a hospital. We want to understand the costs and experiences of women and healthcare staff in both settings.

Induction of Labour3-6 monthsMonitoring phase (IV)No PlaceboStandard MedicinesGynecology and Obstetrics